Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 75 3-Year EBITDA Growth Rate is 130.00% as of Mar. 2026, which is 498% above its 10-year median of 21.75. GuruFocus rates CHIX:BAVAC with a GF Score™ of 75/100 and a GF Value™ of kr170.09. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Bavarian Nordic AS ranks better than 99.2% on this metric.
During the past 12 months, Bavarian Nordic AS's average EBITDA Per Share Growth Rate was 15.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 130.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 51.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bavarian Nordic AS was 150.60% per year. The lowest was -125.50% per year. And the median was 21.75% per year.
Bavarian Nordic AS (CHIX:BAVAc) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bavarian Nordic AS 3-Year EBITDA Growth Rate Related Terms
CHIX:BAVAC vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's 3-Year EBITDA Growth Rate falls into.
Bavarian Nordic AS 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 130.00% mean?
Bavarian Nordic AS (CHIX:BAVAC) has a 3-Year EBITDA Growth Rate of 130.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bavarian Nordic AS and its competitors. This is 498% above median its historical median of 21.75. According to the industry distribution chart, Bavarian Nordic AS ranks #9 out of 1131 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Bavarian Nordic AS's 3-Year EBITDA Growth Rate too high?
Bavarian Nordic AS's current 3-Year EBITDA Growth Rate of 130.00% is 498% above median its 10-year median of 21.75. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Bavarian Nordic AS's value of 130.00% is 772.5% above this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #9 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #9 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Bavarian Nordic AS in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Bavarian Nordic AS's value of 130.00% is 772.5% above this benchmark. While the company's 10-year median is 21.75 vs. the industry median of 14.90, Bavarian Nordic AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current 3-Year EBITDA Growth Rate of 130.00% is 772.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current 3-Year EBITDA Growth Rate is 130.00%, which is 498% above median its own 10-year median of 21.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current 3-Year EBITDA Growth Rate of 130.00%. The stock's GF Value™ is kr170.09, compared to a current price of kr188.30 — trading 10.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 130.00%, which is 498% above median its 10-year median of 21.75 and 772.5% above the Biotechnology industry median of 14.90. Bavarian Nordic AS's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current 3-Year EBITDA Growth Rate is 130.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 10.7% above its estimated GF Value™ of kr170.09.
Key valuation signals for CHIX:BAVAC:
3-Year EBITDA Growth Rate: 130.00% (498% above median its 10-year median of 21.75)
GF Value™: kr170.09 vs. price of kr188.30 (10.7% above fair value)
Industry Position: 772.5% above the Biotechnology median (#9 of 1131)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
75GF Score
Get the complete analysis for CHIX:BAVAC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
